The tragedy of the pandemic coronavirus disease 2019 (COVID-19) led to a desperate search for effective treatments. Chloroquine (CQ), an aminoquinoline used for many years for the prophylaxis and therapy of malaria and autoimmune diseases, has been put forward as a treatment option. The fact that CQ is not patented and has been in clinical use for years is a major advantage. CQ has been shown to have antiviral effects in SARS, MERS, Ebola, and HIV infections, but without data showing clinical effectiveness [1, 2]. Does the current level of evidence suffice for prescribing CQ for COVID-19?
Cortegiani, A., Ippolito, M., Ingoglia, G., Einav, S. (2020). Chloroquine for COVID-19: rationale, facts, hopes. CRITICAL CARE, 24(1) [10.1186/s13054-020-02932-4].
Chloroquine for COVID-19: rationale, facts, hopes
Cortegiani, Andrea
;Ippolito, Mariachiara;Ingoglia, Giulia;
2020-01-01
Abstract
The tragedy of the pandemic coronavirus disease 2019 (COVID-19) led to a desperate search for effective treatments. Chloroquine (CQ), an aminoquinoline used for many years for the prophylaxis and therapy of malaria and autoimmune diseases, has been put forward as a treatment option. The fact that CQ is not patented and has been in clinical use for years is a major advantage. CQ has been shown to have antiviral effects in SARS, MERS, Ebola, and HIV infections, but without data showing clinical effectiveness [1, 2]. Does the current level of evidence suffice for prescribing CQ for COVID-19?
| File | Dimensione | Formato | |
|---|---|---|---|
|
s13054-020-02932-4.pdf
accesso aperto
Tipologia:
Versione Editoriale
Dimensione
464.88 kB
Formato
Adobe PDF
|
464.88 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
